RxDoctor Payments Data

Dale Vincent, APRN

Family · Bardstown, KYNPI 1205164936

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Karyopharm Therapeutics Inc. accounts for 61.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $11,572 and has fallen 71.1% since, to $3,343 in 2025. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,317in general payments, 2019–2025

Across 383 payments — averaging $73.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$17K
  • TG Therapeutics, Inc.$3K
  • AbbVie$572
  • Johnson & Johnson$532
  • AstraZeneca$518
  • Novartis$470
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$1,7456%
  • Speaking & faculty fees$13,27147%
  • Travel & lodging$4,83417%
  • Food & beverage$8,08929%
  • Education$3781%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Karyopharm Therapeutics Inc.26$17,300
TG Therapeutics, Inc.6$3,068
AbbVie24$572
Johnson & Johnson21$532
AstraZeneca(2 entities)22$518
Novartis21$470
Gilead23$435
Merck23$430
Daiichi Sankyo Inc.16$420
E.r. Squibb & Sons, L.L.C.19$392
Incyte Corporation9$378
Pfizer17$324
Bristol Myers Squibb13$274
Regeneron Healthcare Solutions, Inc.9$241
Seagen Inc.8$196
Takeda Pharmaceuticals U.S.A., Inc.8$185
Genentech USA, Inc.8$180
EMD Serono, Inc.4$144
Beigene USA, Inc.3$130
ADC Therapeutics America, Inc.5$126
GSK6$115
Sanofi5$107
Ipsen Biopharmaceuticals, Inc5$99
Genmab U.S., Inc.4$90
Kyowa Kirin, Inc.4$85
Sumitomo Pharma America, Inc.3$83
Stemline Therapeutics Inc.4$83
Puma Biotechnology, Inc.4$69
Pharmaessentia USA Corporation3$64
Astellas Pharma US Inc3$64
Blueprint Medicines Corporation2$63
Array Biopharma Inc4$61
Mirati Therapeutics, Inc.3$61
Taiho Oncology, Inc.2$58
Boehringer Ingelheim2$55
Pharmacyclics LLC, An Abbvie Company3$52
Adaptive Biotechnologies Corporation3$51
Bayer2$50
Coherus Oncology, Inc.2$49
Jazz Pharmaceuticals Inc.3$47
Sobi, Inc2$42
Legend Biotech USA Inc.1$41
Tersera Therapeutics LLC2$40
Lilly USA, LLC2$38
Pharmacosmos Therapeutics Inc.2$38
Cumberland Pharmaceuticals, Inc.2$34
Iovance Biotherapeutics, Inc.1$34
Beone Medicines USA, Inc.1$33
CTI Biopharma Corp.2$31
AVEO Pharmaceuticals, Inc.2$30
Alnylam Pharmaceuticals Inc.1$24
Sun Pharmaceutical Industries Inc.1$23
Deciphera Pharmaceuticals Inc.1$22
Accord Healthcare, Inc.1$21
G1 Therapeutics, Inc.1$20
Fennec Pharmaceuticals, Inc.2$19
Secura Bio, Inc.1$18
Eisai Inc.1$17
Rigel Pharmaceuticals, Inc.1$16
Agios Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,317 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,985
Medicare patients
224
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$340,791
JakafiRuxolitinib Phosphate12$210,131
VenclextaVenetoclax22$203,257
EliquisApixaban22$19,785
Anastrozole90$1,190
Tamoxifen Citrate42$922
Imatinib Mesylate14$875
Ondansetron OdtOndansetron37$771
Acyclovir49$551
Prochlorperazine Maleate40$535
Hydroxyurea29$488
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$323
Dexamethasone14$239
Potassium Chloride16$207
Ondansetron Hcl16$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$64$340,79127 claims
Incyte CorporationJakafi$378$210,13112 claims
AbbVieVenclexta$572$203,25722 claims
PfizerEliquis$324$19,78522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Bardstown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →